CN115969776B - Flurbiprofen sodium gel composition and preparation method thereof - Google Patents
Flurbiprofen sodium gel composition and preparation method thereof Download PDFInfo
- Publication number
- CN115969776B CN115969776B CN202310066880.1A CN202310066880A CN115969776B CN 115969776 B CN115969776 B CN 115969776B CN 202310066880 A CN202310066880 A CN 202310066880A CN 115969776 B CN115969776 B CN 115969776B
- Authority
- CN
- China
- Prior art keywords
- flurbiprofen
- flurbiprofen sodium
- gel composition
- percent
- carbomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of pharmacy, and in particular relates to a flurbiprofen sodium gel composition which comprises the following components in percentage by weight: 0.5 to 4 percent of flurbiprofen sodium (calculated by flurbiprofen), 9800.75 to 2 percent of carbomer, 12 to 25 percent of propylene glycol, 5 to 10 percent of isopropanol, 0.2 to 1 percent of menthol, 1 to 3 percent of pH regulator, 0.1 to 0.5 percent of preservative and the balance of water. The invention innovatively discovers that the carbomer 980 is adopted as a matrix, and other components and the proportion are combined to realize synergy, so that the problems of easy formation of chemical reaction precipitation and unsatisfactory rheological property, which are required to be faced when the flurbiprofen sodium is prepared into a gel preparation, can be solved, and the flurbiprofen sodium gel medicine with excellent rheological property, no precipitation, excellent skin feel, stability, better blood concentration and tissue drug concentration can be obtained.
Description
Technical field:
the invention belongs to the technical field of transdermal administration preparations, and particularly relates to a flurbiprofen sodium gel composition and a preparation method thereof.
The background technology is as follows:
the flurbiprofen sodium is (RS) -2- (2-fluorobiphenyl-4-yl) propionic acid sodium salt dihydrate and is a phenylpropionic acid non-steroidal anti-inflammatory analgesic. Animal studies have shown that it has analgesic, antipyretic and anti-inflammatory effects, and its mechanism of action is mainly to inhibit Cyclooxygenase (COX) activity, block prostaglandin synthesis, and alleviate inflammatory reactions. Widely used for musculoskeletal and joint diseases, but has the same gastrointestinal side effects of peptic ulcer, hemorrhage and the like caused by oral administration as other non-steroidal anti-inflammatory drugs. The transdermal administration preparation can increase local drug concentration of flurbiprofen at pain part, enhance anti-inflammatory effect, and avoid adverse reaction of gastrointestinal tract administration.
The gel is a thick semisolid preparation, has the advantages of high absorption speed, good biocompatibility, uniform texture, easy spreading and washing out, convenient use, good patient compliance and the like, and the main component of the hydrogel preparation is water, a small amount of gel matrix, humectant, bacteriostat and the like, and the possibility of adverse reaction caused by the matrix is obviously reduced. Therefore, the flurbiprofen gel can be researched and developed, the drug effect can be rapidly exerted, the compliance of the gel is enhanced, and the adverse reaction rate is reduced.
The Chinese patent application CN111904925A discloses a flurbiprofen sodium gel preparation, a preparation method and application thereof, and provides a flurbiprofen gel with good transdermal absorption effect, simple preparation process and stable product quality, which comprises the following components: 0.5 to 5 percent of flurbiprofen sodium, 0.5 to 5 percent of matrix, 50 to 95 percent of solvent, 0 to 5 percent of pH regulator, 0.1 to 20 percent of percutaneous absorption permeation enhancer and 0.1 to 1.0 percent of preservative. The gel formulation also suffers from the following disadvantages: (1) the skin is easy to dry and form a film on the surface of the skin after being smeared, and the refreshing feeling is very bad; the prepared gel has low apparent clarity (turbid state) and has the problem of sense discomfort; (2) the prepared gel is easy to cause unsuitable rheological property (the viscosity is too small or too large, the yield stress value is unsuitable, and the problem of poor shearing resistance exists in part of cases), so that the filling is easy to cause unstable filling quantity and poor spreadability in use. In addition, the rheological parameters can influence the contact state and the adhesion state of the product and the skin, and also influence the retention condition of the preparation on the surface of the skin, so that the absorption amount of the medicine entering the skin after being released from the preparation is influenced; unsuitable rheological parameters can result in severe loss of formulation from the skin surface, inability to sustain drug release, or poor spreadability, resulting in poor contact of formulation with skin, and poor formulation wetting ability. (3) Flurbiprofen sodium readily forms a precipitate with the matrix.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention provides the flurbiprofen gel preparation which has proper rheological property, blood concentration and tissue drug concentration which are superior to those of the marketed variety, and simultaneously, the phenomenon that carbomer precipitates white precipitate in the gel preparation process is successfully solved, and the feasibility of industrial production is satisfied.
A flurbiprofen sodium gel composition: comprises the following components in percentage by weight:
0.5 to 4 percent of flurbiprofen sodium (calculated by flurbiprofen)
Carbomer 980.75-2%
Propylene glycol 12-25%
5 to 10 percent of isopropanol
Menthol 0.2-1%
pH regulator 1-3%
0.1 to 0.5 percent of preservative
The balance being water.
Aiming at the problems that flurbiprofen sodium is easy to react and precipitate with matrix materials in a gel matrix, and the rheological property is not ideal, the invention innovatively discovers that carbomer 980 is adopted as the matrix, and other components and proportion are combined to control, so that the synergy can be realized, the problems that the flurbiprofen sodium is easy to form chemical reaction and precipitate and the rheological property is not ideal when the gel preparation is prepared can be solved, and the flurbiprofen sodium gel drug with excellent rheological property, no precipitate, excellent skin feel, stability, better blood concentration and tissue drug concentration can be obtained.
In the invention, the combined control of carbomer 980 and other components and proportions is a key for solving the problems of precipitation, unsatisfactory rheological property and difficult exertion of drug effect of flurbiprofen sodium in the process of forming gel preparation.
Preferably, in the flurbiprofen sodium gel composition, the weight ratio of the propylene glycol to the carbomer 980 to the menthol is 1:0.07-0.085:0.01-0.04.
Preferably, the aqueous solution of carbomer 980 has a viscosity of 40000 to 60000 mPas (0.5% w/V).
Preferably, the pH adjuster is triethanolamine.
Preferably, the preservative is ethyl hydroxy benzoate.
In the invention, the flurbiprofen sodium gel composition consists of the mass percent of flurbiprofen sodium, carbomer 980, propylene glycol, isopropanol, menthol, a pH regulator, a preservative and water.
In the invention, the control of the components and the proportion is the key to cooperatively solve the problems faced by preparing the gel preparation by flurbiprofen sodium, and preferably, the gel preparation comprises the following components in percentage by weight:
0.5 to 2 percent of flurbiprofen sodium (calculated by flurbiprofen)
Carbomer 9801-1.4%
12 to 18 percent of propylene glycol
Isopropyl alcohol 8-10%
Menthol 0.2-0.4%
pH regulator 1-3%
0.1 to 0.3 percent of preservative
The balance being water.
The research of the invention also finds that under the control of the preferable components and the proportion, the rheological property of the flurbiprofen sodium gel can be further synergistically improved, the reaction precipitation is reduced, the skin feel is improved, the stability, the blood medicine and the tissue concentration can be further improved, and the medicine effect is improved.
In the invention, the dynamic viscosity of the flurbiprofen sodium gel composition meets the following conditions:
η 1 30000-45000 mPa.s, eta 50 1700-2500 mPa.s, eta 100 1000-1500 mPa.s; wherein eta 1 The shear rate is 1 (unit; s) -1 ) Dynamic viscosity, eta 50 The shear rate is 50 (units; s) -1 ) Dynamic viscosity, eta 100 The shear rate is 100 (units; s) -1 ) Dynamic viscosity at that time.
In the invention, the yield stress of the flurbiprofen sodium gel composition is 20-33 Pa.
Dynamic viscosity parameter detection conditions: shear rate using rheometer (MCR 102 e): 1s -1 ～100s -1 (linear law change), temperature: 25 ℃, data points: 100, plate: parallel plates, diameter 25mm, clearance: 1mm.
In the present invention, the dynamic viscoelastic parameters of the flurbiprofen sodium gel composition meet the following conditions: the loss factor tan delta at any point within the range of 0.1rad/s to 100rad/s is 0.10 to 0.12. Wherein tan delta is a physical property value calculated from the loss modulus (G ') and the storage modulus (G') according to the following formula.
tanδ＝G″/G′
Dynamic viscoelastic parameter detection conditions: using rheometer (MCR 102 e), angular frequency: 100rad/s to 0.1rad/s (logarithmic rule change), temperature: 25 ℃, data points: 16, taking the point time: none (determined by the device), plate: parallel plates, diameter 25mm, clearance: 1mm, strain: 1%.
The invention also provides a preparation method of the flurbiprofen sodium gel composition, which is characterized in that all the components are uniformly mixed to prepare the flurbiprofen sodium gel composition.
According to the preferred preparation method, carbomer 980 is mixed and dispersed in water to obtain a solution I;
mixing flurbiprofen sodium, propylene glycol, menthol, a preservative, isopropyl alcohol and water to obtain a solution II, and then adding a pH regulator to obtain a solution III;
and mixing the solution I and the solution III to prepare the flurbiprofen sodium gel composition. According to the invention, under the innovation of the formula, the precipitation problem in the preparation process can be further solved unexpectedly by further matching with the control of the preparation process, the preparation effect can be improved, and the uniform gel texture preparation with excellent rheological property can be obtained more efficiently.
According to the preparation method, the problems of precipitation and unsatisfactory rheological property faced by the preparation of the flurbiprofen sodium in gel are solved, and the gel preparation with uniform texture and excellent rheological property can be prepared.
The invention also provides a gel medicine which comprises a container and gel encapsulated in the container and is characterized in that the gel medicine is the flurbiprofen sodium gel composition.
Advantageous effects
Aiming at the problems that flurbiprofen sodium is easy to react and precipitate with matrix materials in a gel matrix, has non-ideal rheological property and the like, the invention innovatively discovers that carbomer 980 is adopted as the matrix, and other components and proportion are combined to control, so that synergy can be realized, and the problems that the flurbiprofen sodium is easy to form chemical reaction and precipitate and has non-ideal rheological property when preparing gel preparations can be solved; can synergistically improve the rheological capacity of flurbiprofen sodium gel, improve blood and tissue concentration and improve skin feel.
Drawings
FIG. 1 is a schematic diagram of gel products of example 2 and comparative examples 1 to 3;
FIG. 2 is a graph of gel angular frequency versus tan delta for each case;
FIG. 3 is a plot of shear rate versus viscosity for gels of each case;
Detailed Description
Description of the preferred embodiments
In the process of preparing the gel, in order to meet the requirement of amplified production and avoid carbomer precipitation of white precipitate in the preparation process, the preparation process is optimized:
(1) adding carbomer 980 into water for pre-dispersing, stirring by a dispersing disc to uniformly disperse the carbomer 980, and adding a proper amount of water for swelling to obtain a solution 1.
(2) Adding flurbiprofen sodium, propylene glycol, menthol and ethylparaben into isopropanol, adding a proper amount of water, stirring and dissolving to obtain a solution 2.
(3) Triethanolamine is added into the solution 2, and stirred for dissolution, thus obtaining the solution 3.
(4) And adding the solution 3 into the solution 1, and stirring and mixing uniformly to obtain the flurbiprofen sodium gel.
The viscosity of the aqueous solution (0.5% W/V) of carbomer 980 is 40000-60000 mPa.s
The list of examples is given in table 1:
TABLE 1
| Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | |
| Flurbiprofen sodium (calculated as flurbiprofen) | 0.5％ | 1％ | 2％ | 3％ | 4％ |
| Carbomer 980 | 0.75％ | 1.0％ | 1.4％ | 1.7％ | 2.0％ |
| Propylene glycol | 12％ | 12％ | 18％ | 20％ | 25％ |
| Isopropyl alcohol | 5％ | 8％ | 10％ | 10％ | 10％ |
| Menthol crystal | 0.2％ | 0.2％ | 0.4％ | 0.5％ | 1.0％ |
| Hydroxy-phenyl ethyl ester | 0.1％ | 0.2％ | 0.2％ | 0.3％ | 0.5％ |
| Triethanolamine salt | 1.0％ | 1.5％ | 2.2％ | 2.6％ | 3.0％ |
| Purified water | To 100% | To 100% | To 100% | To 100% | To 100% |
The preparation process comprises the following steps:
(1) carbomer 980 and water are dispersed in advance, the carbomer 980 and the water are uniformly dispersed by stirring by a dispersing disc, and then a proper amount of water is added for swelling, so that a solution 1 is obtained.
(2) Adding flurbiprofen sodium, propylene glycol, menthol and ethylparaben into isopropanol, adding a proper amount of water, stirring and dissolving to obtain a solution 2.
(3) Triethanolamine is added into the solution 2, and stirred for dissolution, thus obtaining the solution 3.
(4) And adding the solution 3 into the solution 1, and stirring and mixing uniformly to obtain the flurbiprofen sodium gel.
Rheological parameter determination was performed using a rheometer (MCR 102 e):
wherein the dynamic viscosity measurement conditions are as follows: shear rate: 1s -1 ～100s -1 (Linear law change)
Temperature: 25 DEG C
Data points: 100
And (3) a flat plate: parallel plates, diameter 25mm
Gap: 1mm of
The dynamic viscoelastic parameter measurement conditions were as follows:
angular frequency: 100 rad/s-0.1 rad/s (logarithmic rule change)
Temperature: 25 DEG C
Data points: 16
Taking the point time: none (device dependent)
And (3) a flat plate: parallel plates, diameter 25mm
Gap: 1mm of
Strain amount: 1%
The results are shown in Table 2
| Rheological parameters | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 |
| Dynamic viscosity eta 1 (mPa·s) | 43597 | 38480 | 39336 | 32936 | 30498 |
| Dynamic viscosity eta 50 (mPa·s) | 2234.8 | 1983.9 | 2052.1 | 1787.1 | 1760 |
| Dynamic viscosity eta 100 (mPa·s) | 1432 | 1289.9 | 1342 | 1170.7 | 1164.7 |
| Yield stress τ 0 (Pa) | 32.617 | 30.134 | 31.021 | 24.592 | 21.402 |
| Storage modulus G' (Pa) 1 | 241.4 | 203.02 | 207.52 | 198.2 | 177.09 |
| Loss modulus G "(Pa) 1 | 25.279 | 21.467 | 21.998 | 22.169 | 21.067 |
| Loss factor tan delta | 0.105 | 0.106 | 0.106 | 0.112 | 0.119 |
| Creep compliance | 65.51％ | 71.15％ | 74.35％ | 71.67％ | 65.97％ |
| Thixotropic delta 2 | 101.5％ | 100.8％ | 100.4％ | 99.6％ | 96％ |
Remarks: " 1 "results data at an angular frequency of 10 rad/s; " 2 "means the ratio of viscosity recovery 60s after stress is removed.
Filling and sealing the sodium flurbiprofen gel prepared by the prescription process by adopting an automatic filling and sealing machine, judging filling and sealing uniformity by adopting the filling quantity difference, and the result is shown in Table 3:
TABLE 3 Table 3
Requirements for the difference in the loading: the average loading of each 19-22 g and 5-branch should not be lower than 20g.
The results of the flurbiprofen sodium gel preparation process phenomenon and the mixing uniformity prepared by the prescription process are shown in table 4 (under the condition of production scale, after the mixing and stirring of the solution 3 and the solution 1 are finished, samples are taken at 9 different positions and random positions of a stirring tank, the content of 10 samples is detected, and the mixing uniformity is calculated):
TABLE 4 Table 4
| Description of the production Process phenomena | Mixing uniformity (RSD%) | |
| Example 1 | No white precipitate appeared | 0.72％ |
| Example 2 | No white precipitate appeared | 0.58％ |
| Example 3 | No white precipitate appeared | 0.65％ |
| Example 4 | No white precipitate appeared | 0.64％ |
| Example 5 | No white precipitate appeared | 0.86％ |
The preparation (example 2) prepared by the above prescription process and a commercially available flurbiprofen gel patch (manufacturer: japanese three hat pharmaceutical Co., ltd., batch number: 711068) were applied to the blood concentration and local tissue drug concentration data of animal models in tables 5 and 6:
table 5 summary of main pharmacokinetic parameters after 7 consecutive days of percutaneous administration of drug in experimental rabbits (n=6)
TABLE 6 average tissue drug content (ng/g) -time (h) data after 7 consecutive days of transdermal drug administration in experimental rabbits
Conclusion: after the experimental rabbits are continuously and transdermally administrated with flurbiprofen gel plaster and flurbiprofen sodium gel for 7 days, the gel agent can enter the systemic circulation and skin and bone joints (synovium and joint cavity liquid) more quickly, and the tissue medicine is cleared more slowly, so that the analgesic effect is more excellent, and the analgesic effect is faster.
Comparative example list
Viscosity values for each type of carbomer are shown in the following tables (tables 7 and 8):
TABLE 7
TABLE 8
The preparation process comprises the following steps: the rheological properties are shown in Table 9, as in the examples.
TABLE 9
Remarks: " 1 "results data at an angular frequency of 10 rad/s; " 2 "means the ratio of viscosity recovery 60s after stress is removed.
Rheological measurements of examples and comparative examples
The table below shows tan delta at 25 ℃ for examples and comparative examples; fig. 2 shows the relationship between angular frequency and tan delta, and fig. 3 shows the relationship between shear rate and viscosity. The data are shown in Table 10:
table 10
It can be seen that by using innovative control of carbomer 980, further in combination with other ingredients and proportions, synergy can be achieved, and good rheological properties of the formulation can be achieved.
Example 6
The only difference compared to example 2 is that the preparation process is changed, the steps of the difference are:
the preparation process comprises the following steps:
adding carbomer into water for fully swelling, adding triethanolamine, and adjusting pH to obtain gel matrix.
Adding flurbiprofen sodium, menthol and ethylparaben into isopropyl alcohol and propylene glycol, stirring and dissolving to obtain solution 1. Solution 1 was added to the gel matrix and stirred well.
Experiments show that white precipitate appears in the preparation process, and the gel texture can be formed by disappearing after 1.5 times of time.
Claims (11)
1. A flurbiprofen sodium gel composition characterized by comprising, in weight percent:
0.5 to 4 percent of flurbiprofen sodium calculated by flurbiprofen
Carbomer 980 0.75-2%
Propylene glycol 12-25%
5-10% of isopropanol
Menthol 0.2-1%
pH regulator 1-3%
0.1 to 0.5 percent of preservative
The balance being water;
the weight ratio of the propylene glycol to the carbomer 980 to the menthol is 1:0.07-0.085:0.01-0.04.
2. The flurbiprofen sodium gel composition according to claim 1, wherein the aqueous solution of 0.5% w/V carbomer 980 has a viscosity of 40000 to 60000 mpa-s.
3. The flurbiprofen sodium gel composition according to claim 1, wherein the pH adjusting agent is triethanolamine.
4. The flurbiprofen axetil gel composition according to claim 1, wherein the preservative is ethyl hydroxy benzoate.
5. The flurbiprofen sodium gel composition according to claim 1, wherein the flurbiprofen sodium gel composition comprises the following components in percentage by weight:
1-2% of flurbiprofen sodium calculated by flurbiprofen
Carbomer 980 1-1.4%
12-18% of propylene glycol
8-10% of isopropanol
Menthol 0.2-0.4%
pH regulator 1-3%
0.1 to 0.3 percent of preservative
The balance being water.
6. The flurbiprofen sodium gel composition according to claim 1, wherein the composition comprises the following components in percentage by mass.
7. The flurbiprofen sodium gel composition according to any one of claims 1 to 6, wherein the kinetic viscosity of the flurbiprofen sodium gel composition is:
η 1 30000 to 45000 mPa.s,η 50 1700 to 2500 Pa.s,η 100 1000 to 1500 mPas;
the yield stress is 20-33 Pa.
8. The flurbiprofen sodium gel composition according to any one of claims 1 to 6, wherein the dynamic viscoelasticity of the flurbiprofen sodium gel composition is: the loss factor tan delta at any point within the range of 0.1rad/s to 100rad/s is 0.10 to 0.12.
9. A method for preparing a flurbiprofen sodium gel composition according to any one of claims 1 to 8, which is characterized in that the components are uniformly mixed to prepare the flurbiprofen sodium gel composition.
10. The method for preparing the flurbiprofen axetil gel composition according to claim 9, wherein the preparation steps are as follows:
mixing and dispersing carbomer 980 in water to obtain a solution I;
mixing flurbiprofen sodium, propylene glycol, menthol, a preservative, isopropyl alcohol and water to obtain a solution II, and then adding a pH regulator to obtain a solution III;
and mixing the solution I and the solution III to prepare the flurbiprofen sodium gel composition.
11. A gel medicament comprising a container and a gel encapsulated in the container, wherein the gel medicament is the flurbiprofen sodium gel composition according to any one of claims 1 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310066880.1A CN115969776B (en) | 2023-02-06 | 2023-02-06 | Flurbiprofen sodium gel composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310066880.1A CN115969776B (en) | 2023-02-06 | 2023-02-06 | Flurbiprofen sodium gel composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115969776A CN115969776A (en) | 2023-04-18 |
| CN115969776B true CN115969776B (en) | 2023-08-29 |
Family
ID=85972389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310066880.1A Active CN115969776B (en) | 2023-02-06 | 2023-02-06 | Flurbiprofen sodium gel composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115969776B (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001001959A1 (en) * | 1999-07-01 | 2001-01-11 | Farmila Farmaceutici Milano S.P.A. | Ophthalmic compositions in form of aqueous gels |
| CN101947322A (en) * | 2010-09-03 | 2011-01-19 | 南方医科大学 | Gel patch matrix and preparation method and application thereof |
| CN102210646A (en) * | 2011-06-07 | 2011-10-12 | 辽宁成大生物股份有限公司 | Human rabies vaccine gel and preparation method thereof |
| CN102526349A (en) * | 2010-12-31 | 2012-07-04 | 天津药物研究院 | Gel ointment as well as preparation method and application thereof |
| CN102920651A (en) * | 2012-07-23 | 2013-02-13 | 上海工程技术大学 | Flurbiprofen axetil micro-emulsion gel preparation and preparation method thereof |
| CN105232496A (en) * | 2015-09-23 | 2016-01-13 | 成都艾比科生物科技有限公司 | Flurbiprofen coating agent and preparation method thereof |
| CN106667970A (en) * | 2016-12-06 | 2017-05-17 | 北京茗泽中和药物研究有限公司 | Flurbiprofen cataplasm |
| CN106822065A (en) * | 2016-12-06 | 2017-06-13 | 北京茗泽中和药物研究有限公司 | A kind of flurbiprofen cataplasms |
| CN108379381A (en) * | 2018-03-09 | 2018-08-10 | 厦门鼎会龙健康科技有限公司 | Treat prostatitic gel preparation and preparation method thereof |
| CN111012737A (en) * | 2019-02-23 | 2020-04-17 | 湖南九典制药股份有限公司 | Flurbiprofen sodium gel and preparation method thereof |
| CN111904925A (en) * | 2020-04-28 | 2020-11-10 | 湖南九典制药股份有限公司 | Flurbiprofen sodium gel preparation and preparation method and application thereof |
| CN114259413A (en) * | 2021-12-20 | 2022-04-01 | 上海家化联合股份有限公司 | Gel composition |
| CN115475152A (en) * | 2022-11-09 | 2022-12-16 | 北京泰德制药股份有限公司 | External preparation of flurbiprofen and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250804A1 (en) * | 2004-05-06 | 2005-11-10 | Glenmark Pharmaceuticals Limited | Pharmaceutical gel formulations |
| US20120101104A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel compositions and methods of use |
-
2023
- 2023-02-06 CN CN202310066880.1A patent/CN115969776B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001001959A1 (en) * | 1999-07-01 | 2001-01-11 | Farmila Farmaceutici Milano S.P.A. | Ophthalmic compositions in form of aqueous gels |
| CN101947322A (en) * | 2010-09-03 | 2011-01-19 | 南方医科大学 | Gel patch matrix and preparation method and application thereof |
| CN102526349A (en) * | 2010-12-31 | 2012-07-04 | 天津药物研究院 | Gel ointment as well as preparation method and application thereof |
| CN102210646A (en) * | 2011-06-07 | 2011-10-12 | 辽宁成大生物股份有限公司 | Human rabies vaccine gel and preparation method thereof |
| CN102920651A (en) * | 2012-07-23 | 2013-02-13 | 上海工程技术大学 | Flurbiprofen axetil micro-emulsion gel preparation and preparation method thereof |
| CN105232496A (en) * | 2015-09-23 | 2016-01-13 | 成都艾比科生物科技有限公司 | Flurbiprofen coating agent and preparation method thereof |
| CN106667970A (en) * | 2016-12-06 | 2017-05-17 | 北京茗泽中和药物研究有限公司 | Flurbiprofen cataplasm |
| CN106822065A (en) * | 2016-12-06 | 2017-06-13 | 北京茗泽中和药物研究有限公司 | A kind of flurbiprofen cataplasms |
| CN108379381A (en) * | 2018-03-09 | 2018-08-10 | 厦门鼎会龙健康科技有限公司 | Treat prostatitic gel preparation and preparation method thereof |
| CN111012737A (en) * | 2019-02-23 | 2020-04-17 | 湖南九典制药股份有限公司 | Flurbiprofen sodium gel and preparation method thereof |
| CN111904925A (en) * | 2020-04-28 | 2020-11-10 | 湖南九典制药股份有限公司 | Flurbiprofen sodium gel preparation and preparation method and application thereof |
| CN114259413A (en) * | 2021-12-20 | 2022-04-01 | 上海家化联合股份有限公司 | Gel composition |
| CN115475152A (en) * | 2022-11-09 | 2022-12-16 | 北京泰德制药股份有限公司 | External preparation of flurbiprofen and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 姚静.《药用辅料应用指南》.北京：中国医药科技出版社,2011,第116页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115969776A (en) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2463038C2 (en) | Diclofenac gel | |
| FI119498B (en) | Compositions for the treatment of hemorrhoids and method of use | |
| US4008321A (en) | Composition for a topical preparation and a process for producing the same | |
| Pawar et al. | Design and evaluation of topical diclofenac sodium gel using hot melt extrusion technology as a continuous manufacturing process with Kolliphor® P407 | |
| JP2004505900A (en) | Topical gel delivery system | |
| JPS5850964B2 (en) | Steroid-containing cream preparation and its manufacturing method | |
| Maqbool et al. | Semisolid dosage forms manufacturing: Tools, critical process parameters, strategies, optimization, and recent advances | |
| JPH0555483B2 (en) | ||
| JP6228351B2 (en) | Method for producing topical antithyroid ointment | |
| BR102018008324A2 (en) | topical pharmaceutical composition and topical pharmaceutical composition manufacturing process | |
| KR20040023740A (en) | Polysaccharide-Containing Compositions and Use Thereof | |
| JP4195178B2 (en) | Anti-inflammatory analgesic topical | |
| EP3097907B1 (en) | A gel formulation comprising analgesic and anesthesic agents | |
| CN115969776B (en) | Flurbiprofen sodium gel composition and preparation method thereof | |
| JP2004517829A (en) | Dermatological prescription | |
| BR112020025884A2 (en) | composition for topical application, packaging, and method for making a composition | |
| CN102247374B (en) | Application of tetrahydropyrimidin and derivative thereof in preparation of medicament for treating skin wound | |
| Munshi et al. | Formulation and Evaluation of Diclofenac gel | |
| CN108210929A (en) | A kind of pharmaceutical composition containing Etoricoxib and preparation method thereof | |
| Orlenko et al. | Study of structural and mechanical properties of bases in the development of dental gel with combined composition | |
| CN116059383B (en) | Flurbiprofen salt gel and crystallization inhibitor thereof | |
| Srivastava | Excipients for semisolid formulations | |
| JPH09110702A (en) | Gel preparation containing seawater in deep ocean | |
| Hanif et al. | Influence of different gelling polymers on dexibuprofen gel formulation: In-vitro characterization and stability profile. | |
| WO2024118019A1 (en) | Dermal thermosensitive gel formulations for the treatment of inflammation-related edema and various pains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |